Abrasilver Resource Corp Stock (OTC: ABBRD)

Latest news for Abrasilver Resource Corp (OTC:ABBRD) Stock

Abrasilver Resource Corp

Keefe, Bruyette &amp; Woods analyst Catherine Mealor maintains Sandy Spring Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SASR#NASDAQ">SASR</a>) with a Market Perform and raises the price target from $25 to $30.

News

Price Target

Analyst Ratings

SASR

Keefe, Bruyette & Woods Maintains Market Perform on Sandy Spring Bancorp, Raises Price Target to $30

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a <a href="https://www.benzinga.com/yield-investments">high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the energy sector.
<h3 class="wp-block-heading">CVR Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVI#NYSE">CVI</a>)</h3>
<ul>
<li>Dividend Yield: 7.88%</li>
<li>Scotiabank analyst Paul Cheng maintained a Sector Underperform rating and cut the price target from $29 to $24 on July 12. This analyst has an accuracy rate of 61%.</li>
<li>JP Morgan analyst Phil Gresh maintained an Underweight rating and slashed the price target from $30 to $26 on July 2. This analyst has an accuracy rate of 60%.</li>
<li>Recent News: CVR Energy will release its second quarter earnings results on Monday, July 29, after the closing bell.</li>
<li>Benzinga Pro's real-time newsfeed <a href="https://pro.benzinga.com/dashboard">alerted to latest CVI news</a></li>
</ul>
<h3 class="wp-block-heading">DHT Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHT#NYSE">DHT</a>)</h3>
<ul>
<li>Dividend Yield: 10.00%</li>
<li>Stifel analyst Benjamin Nolan maintained a Hold rating and raised the price target from $12 to $13 on July 24. This analyst has an accuracy rate of 77%.</li>
<li>Jefferies analyst Omar Nokta upgraded the stock from Hold to Buy and increased the price target from $11 to $14 on March 21. This analyst has an accuracy rate of 79%.</li>
<li>Recent News: On July 24, DHT Holdings issued a business update.</li>
<li><a href="https://pro.benzinga.com/dashboard">Benzinga Pro's charting tool</a> helped identify the trend in DHT's stock.</li>
</ul>
<h3 class="wp-block-heading">Antero Midstream Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AM#NYSE">AM</a>)</h3>
<ul>
<li>Dividend Yield: 6.18%</li>
<li>Goldman Sachs analyst John Mackayreinstated a Neutral rating with a price target of $12.5 on Oct. 6, 2023. This analyst has an accuracy rate of 70%.</li>
<li>UBS analyst Brian Reynolds maintained a Buy rating and cut the price target from $15 to $14 on Oct. 5, 2023. This analyst has an accuracy rate of 76%.</li>
<li>Recent News: Antero Resources will issue its second quarter earnings on Wednesday, July 31.</li>
<li>Benzinga Pro's signals feature notified of a potential <a href="https://pro.benzinga.com/dashboard">breakout in AM shares</a>.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39954998/over-1m-bet-on-united-security-bancshares-check-out-these-3-stocks-insiders-are-buying">Over $1M Bet On United Security Bancshares? Check Out These 3 Stocks Insiders Are Buying</a></li>
</ul>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>

Dividends

Markets

Trading Ideas

Wall Street's Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 6% Dividend Yields

In the second quarter, the U.S. gross domestic product (GDP) saw a robust real growth of 2.8%, accelerating from the previous quarter&#8217;s 1.4% growth and <a href="https://www.benzinga.com/economics/macro-economic-events/24/07/39957034/us-economy-expands-2-8-in-q2-tops-estimates-weekly-jobless-claim-fall">surpassing the 2% estimates.</a>
Inflation pressures, measured by the Personal Consumption Expenditure (PCE) price index, eased from 3.4% to 2.6%, indicating progress towards the Federal Reserve&#8217;s 2% target. Core PCE inflation, excluding food and energy items, also fell from 3.7% to 2.9%, though it slightly missed the expected drop to 2.7%.
&#8220;The US economy is much stronger than people realize. Those concerned about a growth slowdown should feel reassured by this morning's GDP number,&#8221; said Chris Zaccarelli, chief investment officer for Independent Advisor Alliance.
Despite the strong economic performance, market expectations for upcoming Federal Reserve rate cuts remain unchanged, with the probability of a September rate cut holding steady at 100%.
Following the GDP report, U.S. equity futures turned positive, reflecting a resurgence in risk sentiment after days of significant volatility. At 09:00 a.m. ET, contracts on the tech-heavy Nasdaq 100 rose 0.2%, while those on the S&amp;P 500 and the Dow each increased by 0.1%.
<h3 class="wp-block-heading">7 ETFs On The Move Thursday</h3>
Significant moves in exchange-traded funds (ETFs) during Thursday premarket trading included:
<ul>
<li>The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) up 0.9%</li>
<li>The Financials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) up 0.5%</li>
<li>The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) up 0.5%</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) up 0.6%</li>
<li>The SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) down 1.2%</li>
<li>The iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>) down 4.5%</li>
<li>The iShares Bitcoin Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>) up 2.4%</li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39955365/bitcoin-tumbles-3-ethereum-plunges-below-3-200-what-is-going-on-with-etfs">Bitcoin Tumbles 3%, Ethereum Plunges Below $3,200: What Is Going On With ETFs?</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Macro Economic Events

Bonds

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Federal Reserve

Tech

ETFs

IBIT

iShares Trust Barclays 20+ Year Treasury Bond Fund

Surprise Q2 GDP Growth, Inflation Eases — 'Economy Is Much Stronger Than People Realize': 7 ETFs On The Move

Wedbush analyst Matt Bryson reiterates Diebold Nixdorf (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBD#NYSE">DBD</a>) with a Outperform and maintains $50 price target.

Reiteration

Wedbush Reiterates Outperform on Diebold Nixdorf, Maintains $50 Price Target

JP Morgan analyst Jessica Fye maintains Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) with a Neutral and raises the price target from $31 to $32.

ALKS

JP Morgan Maintains Neutral on Alkermes, Raises Price Target to $32

Keefe, Bruyette &amp; Woods analyst Catherine Mealor maintains Renasant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNST#NYSE">RNST</a>) with a Market Perform and raises the price target from $34 to $36.

RNST

Keefe, Bruyette & Woods Maintains Market Perform on Renasant, Raises Price Target to $36

TOPS

TOPS Ships Halted Pending News

Wedbush analyst Alicia Reese reiterates AMC Enter Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) with a Neutral and maintains $4 price target.

Wedbush Reiterates Neutral on AMC Enter Hldgs, Maintains $4 Price Target

Marathon Digital Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) shares are trading lower Thursday amid a drop in the price of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>). The company announced the purchase of $100 million of Bitcoin as it adopts a <a href="https://www.benzinga.com/pressreleases/24/07/g39955751/mara-purchases-100-million-of-bitcoin">buy-and-hold strategy</a>.
What Happened: Marathon Digital announced that it has purchased $100 million of Bitcoin and now currently holds over 20,000 Bitcoin on its balance sheet. 
Effective immediately, the company will adopt a &#8220;full HODL&#8221; approach to its Bitcoin treasury policy, retaining all Bitcoin it mines and periodically making strategic open market purchases. 
&#8220;Adopting a full HODL strategy reflects our confidence in the long-term value of bitcoin,&#8221; said Fred Thiel, chairman and CEO of Marathon Digital. 
&#8220;We believe bitcoin is the world&#8217;s best treasury reserve asset and support the idea of sovereign wealth funds holding it. We encourage governments and corporations to all hold bitcoin as a reserve asset.&#8221;
Marathon noted that Bitcoin&#8217;s recent price decline combined with the strength of the company&#8217;s balance sheet created an opportunity to add to Bitcoin holdings and focus on growth holdings on the balance sheet. The company believes Bitcoin is supported by current tailwinds including increased institutional support and an improving macro environment.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39955365/bitcoin-tumbles-3-ethereum-plunges-below-3-200-what-is-going-on-with-etfs">Bitcoin Tumbles 3%, Ethereum Plunges Below $3,200: What Is Going On With ETFs?</a>
<h2 class="wp-block-heading">Is MARA A Good Stock To Buy?</h2>
Wall Street analysts view Marathon Digital on the whole as a Buy, given the history of coverage over the past three months. Brian Dobson from Chardan Capital is the most bearish, expecting a 30% fall in the stock in the coming year.
But looking at how the market as a whole thinks of the stock, you can reference historical price action for views on whether investors feel strongly about the stock one way or another. In the past three months, Marathon Digital rose 12.17%, which indicates that opinion improved on the business and how attractive it is to own based on either its stock price, or underlying fundamentals, like revenue, which rose 223.08% over the past year.
A complete overview of how Wall Street views individual stocks is available <a href="https://www.benzinga.com/analyst-stock-ratings">here</a>, while real time updates on the latest analyst actions will be delivered via <a href="https://pro.benzinga.com">Benzinga PRO</a>. Try it for free.
MARA Price Action: Marathon Digital shares were down 1.33% at $20.40 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Movers

$BTC

MARA

Marathon Digital Buys Bitcoin, Adopts 'Full HODL' Strategy: What's Going On With The Mining Stock?

Keefe, Bruyette &amp; Woods analyst Bose George maintains PennyMac Mortgage IT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PMT#NYSE">PMT</a>) with a Outperform and lowers the price target from $15.5 to $15.

Keefe, Bruyette & Woods Maintains Outperform on PennyMac Mortgage IT, Lowers Price Target to $15

AST SpaceMobile Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) shares are rising Thursday. The company announced the successful completion of its <a href="https://www.benzinga.com/pressreleases/24/07/b39954656/ast-spacemobile-announces-first-five-commercial-satellites-completed-final-assembly-and-ready-for-">first five commercial satellites</a>.
What To Know: AST SpaceMobile has completed its first five commercial satellites it calls Bluebirds. The satellites are ready for shipment to Cape Canaveral during the first week of August, with a seven-day launch window in September.
AST SpaceMobile noted that the Bluebird satellites have undergone rigorous testing to ensure they meet the demanding requirements of operations in space. The satellites are now in final preparations for shipment. 
&#8220;This is a momentous occasion for AST SpaceMobile. These first five satellites are built on the success of our in-orbit BlueWalker 3 satellite and will provide U.S. nationwide non-continuous service with over 5,600 cells in premium low-band spectrum, with a planned 10-fold increase in processing bandwidth,&#8221; said Abel Avellan, chairman and CEO of AST SpaceMobile.&nbsp;
&#8220;We are eager to see these pioneering satellites take flight and begin laying the foundation for our global cellular broadband network.&#8221;
On July 18, AST SpaceMobile decided on an updated launch window in September. The exact launch date will be confirmed closer to the launch window and shared with the public. The timing is consistent with previous&nbsp;guidance to deliver satellites in July or August with an orbital launch scheduled shortly thereafter.&nbsp;
See Also: <a href="https://www.benzinga.com/news/24/07/39956687/bank-of-america-accenture-and-2-other-stocks-insiders-are-selling">Bank of America, Accenture And 2 Other Stocks Insiders Are Selling</a>
<h2 class="wp-block-heading">How to Buy ASTS Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in AST SpaceMobile's case, it is in the Communication Services sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
ASTS Price Action: AST SpaceMobile shares are up more than 500% in just the last three months. The stock was up 2.92% at $13.75 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of AST SpaceMobile.

SPACE

General

ASTS

AST SpaceMobile Stock Is Moving Higher Thursday: What's Going On?

Wedbush analyst Scott Devitt reiterates Pinterest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) with a Neutral and maintains $46 price target.

PINS

Wedbush Reiterates Neutral on Pinterest, Maintains $46 Price Target

Keefe, Bruyette &amp; Woods analyst Sanjay Sakhrani maintains Navient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAVI#NASDAQ">NAVI</a>) with a Market Perform and raises the price target from $15 to $16.

NAVI

Keefe, Bruyette & Woods Maintains Market Perform on Navient, Raises Price Target to $16

Chipotle Mexican Grill Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) shares traded higher before paring gains Thursday morning on the heels of the company&#8217;s second-quarter financial results. Here&#8217;s what <a href="https://www.benzinga.com/pressreleases/24/07/n39942304/chipotle-announces-second-quarter-2024-results">you need to know</a>.
What Happened: After the market close on Wednesday, Chipotle reported second-quarter revenue of $2.97 billion, beating the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $2.94 billion.&nbsp;The company also beat analyst estimates for earnings of 32 cents per share with reported earnings of 34 cents per share.
According to data from&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>, Chipotle has now beat estimates on the top and bottom lines in four consecutive quarters.
Comparable restaurant sales increased 11.1% year-over-year driven by over 8% transaction growth as margins expanded. Operating margin was 19.7% in the second quarter, up from 17.2% year-over-year.
Chipotle noted that it repurchased $151.4 million of its stock during the second quarter and said it had $647.7 million remaining under its share repurchase authorization after its board authorized an additional $400 million in repurchases in June. 
Chipotle reiterated expectations for full-year 2024 comparable restaurant sales growth in the mid to high single-digit range. The company said it still anticipates opening between 285 and 315 new restaurants in 2024 with over 80% including a Chipotlane.
Check This Out: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39951461/markets-are-sounding-an-alarm-peter-schiff-warns-federal-reserve-should-cut-rates-b">&#8216;Markets Are Sounding An Alarm:&#8217; Peter Schiff Warns Federal Reserve Should Cut Rates Before Recession Hits</a>
Analyst Changes: Multiple analysts adjusted price targets on the stock following the print.
<ul>
<li>Wedbush analyst Nick Setyan maintained Chipotle with a <a href="https://www.benzinga.com/analyst-stock-ratings">Neutral</a> and lowered the price target from&nbsp;$64&nbsp;to&nbsp;$54.</li>
</ul>
<ul>
<li>Stephens &amp; Co. analyst Jim Salera maintained Chipotle with an Equal-Weight and lowered the price target from&nbsp;$64&nbsp;to&nbsp;$61.</li>
</ul>
<ul>
<li>TD Cowen analyst Andrew Charles maintained Chipotle with a Buy and lowered the price target from&nbsp;$72&nbsp;to&nbsp;$65.</li>
</ul>
<ul>
<li>Piper Sandler analyst Brian Mullan maintained Chipotle with a Neutral and lowered the price target from&nbsp;$61&nbsp;to&nbsp;$56.</li>
</ul>
CMG Price Action: <a href="https://www.benzinga.com/quote/CMG" target="_blank" rel="noreferrer noopener">Chipotle shares</a> initially climbed more than 13% on the report, before pulling back. The stock was down 0.44% at $51.55 at the time of publication, according to <a href="https://benzinga.grsm.io/gxjhpowx7zks" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Shutterstock.

Earnings

What's Going On With Chipotle Stock Thursday?

On Thursday,&nbsp;AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>)&nbsp;reported second-quarter sales of $12.94 billion, up 13% year over year (+17% at constant currency), beating the consensus of $12.75 billion.&nbsp;
The company&#8217;s adjusted EPADS <a target="_blank" href="https://www.astrazeneca.com/content/dam/az/PDF/2024/h1/H1-and-Q2-2024-results-announcement.pdf" rel="noreferrer noopener">reached</a> $0.99, inline with consensus. The adjusted EPS was $1.98 (1 ADR = 2 Common Shares)
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/06/39503672/china-approves-astrazenecas-tagrisso-chemotherapy-combo-regime-for-previously-untreated-lung-cancer" rel="noreferrer noopener">China Approves AstraZeneca&#8217;s Tagrisso-Chemotherapy Combo Regime For Previously Untreated Lung Cancer Patients</a>.
AstraZeneca&#8217;s top business, oncology, delivered a 15% jump (up 19% on constant currency) in second-quarter sales to $5.33 billion.
<ul>
<li>Tagrisso, Imfinzi, and Calquence were the top-selling cancer drugs, generating $1.61 billion, $1.15 billion, and $790 million, respectively.</li>
<li>Tagrisso is up 8% (12% at CER) due to strong global demand, and Calquence is up 21% (22% at CER) with sustained leadership in 1L CLL. Enhertu&#8217;s revenue reached $472 million, up 46% (49% at CER).</li>
</ul>
Cardiovascular, Renal, and Metabolism (CVRM) sales increased 18% (up 22 at CER)% to&nbsp;$3.16 billion.
<ul>
<li>Farxiga sales were up 29% (32% at CER) to $1.95 billion, and Lokelma sales increased 36% (41% at CER).</li>
</ul>
R&amp;I Respiratory &amp; Immunology sales increased 23% (26% CER) to $1.91 billion.
<ul>
<li>Breztri revenue is up 44% (47% at CER). Saphnelo sales increased 65%, Tezspire sales were up 97% (>2x at CER), and Symbicort revenues were up 20% (25% CER) to $722 million.</li>
</ul>
Rare Disease drug sales increased by 10% (+14% at CER) to&nbsp;$2.15 billion.
<ul>
<li>Ultomiris revenue is up 33% to $946 million (36% at CER), partially offset by a decline in Soliris of 14% (8% at CER) to $700 million.</li>
<li>Strensiq up 13% (14% at CER) and Koselugo up 43% (45% at CER).</li>
</ul>
Guidance:&nbsp;For fiscal year 2024, AstraZeneca forecasts total revenue and core EPS to increase by a mid-teens percentage, compared to prior guidance of a low double-digit to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38430571/astrazeneca-posts-bumper-earnings-on-strong-sales-from-cancer-drugs-sticks-to-annual-guidance" rel="noreferrer noopener">low-teens percentage</a>.
Reuters highlights the sales outlook, which indicates that the company has transitioned beyond its peak-selling COVID vaccine from 2021, driven by its cancer therapies and a robust pipeline with new treatments for various diseases expected by the decade&#8217;s end.
Price Action: AZN stock is down 4.44% at $76.16 during the premarket session at last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39579925/astrazenecas-covid-19-prevention-drug-for-patients-with-weak-immune-systems-european-medicines-ag" target="_blank" rel="noreferrer noopener">AstraZeneca&#8217;s COVID-19 Prevention Drug For Patients With Weak Immune Systems &#8211; European Medicines Agency Accepts Marketing Application Under Accelerated Assessment</a>.</li>
</ul>
Image by Robert Way via Shutterstock

Biotech

Large Cap

Guidance

Health Care

AstraZeneca Posts Mixed Q2 Earnings, Still Raises Annual Guidance On Strong Demand For Cancer, Rare Disease Medicines

Keefe, Bruyette &amp; Woods analyst Wood Lay maintains First Western Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYFW#NASDAQ">MYFW</a>) with a Outperform and lowers the price target from $25 to $23.

MYFW

Keefe, Bruyette & Woods Maintains Outperform on First Western Financial, Lowers Price Target to $23

Wedbush analyst Daniel Ives maintains Check Point Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) with a Outperform and raises the price target from $185 to $200.

CHKP

Wedbush Maintains Outperform on Check Point Software, Raises Price Target to $200

By <a href="https://roboforex.com/?utm_source=benzinga.com&amp;utm_medium=pr&amp;utm_campaign=rf_en_external_article_25072024&amp;utm_content=analysis&amp;utm_term=forecast">RoboForex</a> Analytical Department
GBP/USD pair is down to 1.2892 on Thursday. Selling intensified on the 18th of July. Since then, GBP has remained under pressure, although it is making attempts to stabilise.
Statistics released earlier showed that UK private sector activity improved in July. PMI data indicated that activity in the services sector expanded slightly, while in the industrial segment, it was the highest since February 2022.
The data aligned with forecasts and confirmed the positive sentiment in industrial production after Labour&#39;s convincing election victory.
The market is watching the situation with the Bank of England interest rate. The probability of a rate reduction at the August meeting is at most 40%. The UK regulator holds a neutral view of the monetary policy structure and is unlikely to make decisions that could have a mixed effect.
Overall, GBP remains under pressure from the US Dollar, which is receiving support from various sides.
<h3>GBP/USD Technical Analysis</h3>
<a href="https://www.benzinga.com/files/u117641/gbpusdh4_9.png"><img alt="" src="https://www.benzinga.com/files/u117641/gbpusdh4_9.png" style="height:278px; width:624px" /></a>
On the H4 chart of GBP/USD, the market has formed a consolidation range around the 1.2911 level. Today, the market broke out of this range downwards. The potential for a downside wave to 1.2777 is almost open. The target is the first one. After reaching this level, we will consider the probability of correction to 1.2911 (test from below). Technically, this scenario is confirmed by the MACD indicator. Its signal line is above the zero mark and is directed strictly downwards.
<a href="https://www.benzinga.com/files/u117641/gbpusdh1_9.png"><img alt="" src="https://www.benzinga.com/files/u117641/gbpusdh1_9.png" style="height:278px; width:624px" /></a>
On the H1 chart of GBP/USD, a correction wave to the level of 1.2937 is performed. Today, the structure of decrease to the level of 1.2858 is formed. After working off this level, we will consider the probability of a growth link to the level of 1.2897. At this point, the correction potential will be exhausted. After the correction is over, we will consider the beginning of a new wave of decline to 1.2824 with the prospect of trend continuation to the level of 1.2777. Technically, this scenario is confirmed by the Stochastic oscillator. Its signal line is under the level of 50 and continues to decline to the level of 20.
Disclaimer
Any forecasts contained herein are based on the author&#39;s particular opinion. This analysis may not be treated as trading advice. RoboForex bears no responsibility for trading results based on trading recommendations and reviews contained herein.
This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.

GBP/USD Faces Downward Pressure Amid US Dollar Strength

Keefe, Bruyette &amp; Woods analyst Aidan Hall reiterates Moelis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MC#NYSE">MC</a>) with a Market Perform and raises the price target from $54 to $60.

Keefe, Bruyette & Woods Reiterates Market Perform on Moelis, Raises Price Target to $60

AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) reported quarterly adjsuted earnings of $0.99 per share which missed the analyst consensus estimate of $1.20 by 17.5 percent. This is a 7.91 percent decrease over earnings of $1.07 per share from&lt;p&gt;AstraZeneca (NASDAQ:&lt;a class=&quot;ticker&quot; href=&quot;https://www.benzinga.com/stock/AZN#NASDAQ&quot;&gt;AZN&lt;/a&gt;) reported quarterly adjsuted earnings of $0.99 per share which missed the analyst consensus estimate of $1.20 by 17.5 percent. This is a 7.91 percent decrease over earnings of $1.07 per share from the same period last year. The company reported quarterly sales of $12.98 billion which beat the analyst consensus estimate of $12.75 billion by 1.83 percent. This is a 13.73 percent increase over sales of $11.42 billion the same period last year.&lt;/p&gt;

CORRECTION: AstraZeneca Q2 Adj. EPS $1.98 Inline, Adj. EPADS $0.99, Sales $12.98B Beat $12.60B Estimate

AbraSilver: One Of A Few Precious Metals Developers With Good Recent Performance

AbraSilver Resource (TSE:ABRA) has released an update. AbraSilver Resource Corp. has released its unaudited financial results for Q1 2024, along wi...

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Abrasilver Resource Corp

News

Latest news for Abrasilver Resource Corp (OTC:ABBRD) Stock